Theravance Biopharma
TBPH
115 hedge funds and large institutions have $439M invested in Theravance Biopharma in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 43 reducing their positions, and 15 closing their positions.
4.89% more ownership
Funds ownership: 91.32% → 96.22% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less funds holding
Funds holding: 119 → 115 (-4)
20% less capital invested
Capital invested by funds: $546M → $439M (-$108M)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
30% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$2.96M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$2.95M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.53M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$2.19M |
| 5 |
Millennium Management
New York
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.16M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.63M |
| 3 |
BlackRock
New York
|
-$4.97M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$4.67M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.67M |
TBPH Hedge Fund Activity: Q3 2023 in Review
115 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2023, worth a combined $439M — down 20% from $546M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TBPH and 12 opened new positions — a net loss of 3 holders — while 43 trimmed existing stakes and 30 added.
The largest buyer was Oasis Management Company, adding an estimated $2.96M. The largest seller was Fidelity Investments, cutting an estimated $9.16M.
- 115 institutional investors held Theravance Biopharma (TBPH) as of Q3 2023, down from 119 in Q2 2023.
- Funds reported $439M of Theravance Biopharma stock for Q3 2023, down 20% quarter-over-quarter.
- 12 funds opened new Theravance Biopharma positions in Q3 2023 and 15 closed out, a net change of -3 holders.
- The largest Theravance Biopharma buyer in Q3 2023 was Oasis Management Company, an estimated $2.96M added.
- The largest Theravance Biopharma seller in Q3 2023 was Fidelity Investments, an estimated $9.16M sold.
Based on aggregated 13F filings for Q3 2023.